Abstract
Conventional cancer treatments rely on radiotherapy and chemotherapy. Such treatments supposedly mediate their effects via the direct elimination of tumor cells. Here we show that the success of some protocols for anticancer therapy depends on innate and adaptive antitumor immune responses. We describe in both mice and humans a previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs). During chemotherapy or radiotherapy, DCs require signaling through TLR4 and its adaptor MyD88 for efficient processing and cross-presentation of antigen from dying tumor cells. Patients with breast cancer who carry a TLR4 loss-of-function allele relapse more quickly after radiotherapy and chemotherapy than those carrying the normal TLR4 allele. These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249–1255 (1999).
Albert, M.L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86–89 (1998).
Ronchetti, A. et al. Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. J. Leukoc. Biol. 66, 247–251 (1999).
Gorla, R. et al. Differential priming to programmed cell death of superantigen-reactive lymphocytes of HIV patients. AIDS Res. Hum. Retroviruses 10, 1097–1103 (1994).
Winau, F. et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24, 105–117 (2006).
Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701 (2005).
Gardai, S.J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321–334 (2005).
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007).
Medzhitov, R. & Janeway, C.A., Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295–298 (1997).
Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001).
Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211–220 (2002).
Blander, J.M. & Medzhitov, R. On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 7, 1029–1035 (2006).
West, M.A. et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 305, 1153–1157 (2004).
Yarovinsky, F., Kanzler, H., Hieny, S., Coffman, R.L. & Sher, A. Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 25, 655–664 (2006).
Beutler, B. et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24, 353–389 (2006).
Huang, B. et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009–5014 (2005).
Barrat, F.J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131–1139 (2005).
Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S. & Nakanishi, Y. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J. Immunol. 172, 2039–2047 (2004).
Delamarre, L., Couture, R., Mellman, I. & Trombetta, E.S. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203, 2049–2055 (2006).
Seong, S.Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469–478 (2004).
Jiang, D. et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11, 1173–1179 (2005).
Biragyn, A. et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 1025–1029 (2002).
Park, J.S. et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290, C917–C924 (2006).
Tsung, A. et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201, 1135–1143 (2005).
Scaffidi, P., Misteli, T. & Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195 (2002).
Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251 (1999).
Rovere-Querini, P. et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825–830 (2004).
Arbour, N.C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25, 187–191 (2000).
Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185–192 (2002).
Erridge, C., Stewart, J. & Poxton, I.R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J. Exp. Med. 197, 1787–1791 (2003).
van der Graaf, C. et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 30, 264–268 (2005).
Cheng, I., Plummer, S.J., Casey, G. & Witte, J.S. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 16, 352–355 (2007).
Kurts, C., Miller, J.F., Subramaniam, R.M., Carbone, F.R. & Heath, W.R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188, 409–414 (1998).
Shi, Y. & Rock, K.L. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32, 155–162 (2002).
Tabeta, K. et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7, 156–164 (2006).
Janssen, E. et al. Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. Immunity 24, 787–799 (2006).
Shi, Y., Evans, J.E. & Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516–521 (2003).
la Sala, A. et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J. Immunol. 166, 1611–1617 (2001).
Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823–835 (2006).
Bauer, A.K. et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J. Natl. Cancer Inst. 97, 1778–1781 (2005).
Gardella, S. et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995–1001 (2002).
Messmer, D. et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307–313 (2004).
Dumitriu, I.E., Bianchi, M.E., Bacci, M., Manfredi, A.A. & Rovere-Querini, P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81, 84–91 (2007).
Hoshino, K. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162, 3749–3752 (1999).
Granda, T.G. et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 86, 999–1005 (2002).
Lutz, M.B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77–92 (1999).
Porgador, A., Yewdell, J.W., Deng, Y., Bennink, J.R. & Germain, R.N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715–726 (1997).
Van Rijn, B.B., Roest, M., Franx, A., Bruinse, H.W. & Voorbij, H.A. Single step high-throughput determination of Toll-like receptor 4 polymorphisms. J. Immunol. Methods 289, 81–87 (2004).
Acknowledgements
We thank P. Aucouturier for helpful discussions; P. Tiberghien for providing DNA samples for genotyping; E. Vicaut for help in statistical analyses; S. Viaud and C. Chenot for technical assistance; the IGR animal facility for help in breeding transgenic mice; G. Lauvau (INSERM, University of Sofia Antipolis, Valbonne, France) for providing BALB/c TLR2−/− mice; S. Akira (Osaka University, Japan) and B. Ryffel (CNRS Orleans, France) for C57BL/6 Tlr1−/−, Tlr2−/−, Tlr3−/−, Tlr4−/− (ref. 44), Tlr5−/−, Tlr6−/−, Tlr7−/−, Tlr9−/−, Trif−/− and Myd88−/− mice; C. Théry (Institut Curie, Paris, France) for providing OVA-transfected TS/A cell and EL4 cells; E. Tartour (Hôpital Européen Georges-Pompidou, Assistance Publique–Hôpitaux de Paris, France) for providing B3Z and B09710 clones and A. Carpentier (Centre Hospitalier Universitaire Pitié Salpétrière, Paris, France) for providing CpG oligodeoxynucleotide 28. This work was supported by special grants from the Ligue contre le Cancer (G.K., L.Z.), Association pour le recherche contre le cancer (G.M.), Institut National contre le Cancer (L.Z., G.K.), Fondation pour la Recherche Médicale (G.K., L.Z., A.T.), Institut National de la Santé et de la Recherche Médicale (F.G.), Association for International Cancer Research (G.K., L.Z.) and European Union (DC-Thera, Allostem for L.Z., RIGHT for G.K.).
Author information
Authors and Affiliations
Contributions
L.A., F.G., A.T., M.O., G.M., M.C.M. and E.U. performed the in vivo and in vitro experiments. C.O. performed in vitro experiments. A.C. performed immunoprecipitations. B.R. provided transgenic mice. F.J.B., H.Y. and F.L. provided essential reagents. R.L., C.N., J.-P.M., A.C., V.J., F.C.-C., S.D. and T.T. recorded and provided the patients' data. L.A. and P. Saulnier performed patients' genotyping. A.T., F.A. and F.G. conducted data analysis. S.A. offered scientific advice and gave technical hints on the direction of the study. L.Z. and G.K. conceived the study and wrote the manuscript. P. Saftig provided the LAMP2−/− mice. J.B. set up the radiotherapy protocols in vivo.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–5, Supplementary Table 1 and Supplementary Methods (PDF 4638 kb)
Rights and permissions
About this article
Cite this article
Apetoh, L., Ghiringhelli, F., Tesniere, A. et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050–1059 (2007). https://doi.org/10.1038/nm1622
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1622